Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Accrued Expenses and Long-term Liabilities

9 Months Ended

Sep. 30, 2016

7.	ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015:

	September 30, 2016		December 31, 2015
Accrued royalties	$	504	$	111
Self insurance and benefit accruals		272		366
Indemnification liability		875		875
Contingent consideration		209		659
Rent payable		78		127
DOJ settlement		665		250
Accrued professional fees		1,320		775
Taxes payable		691		591
Unclaimed property		544		546
Directors fees and insurance		208		107
All others		1,539		1,554
	$	6,905	$	5,961

Long-term liabilities consisted of the following as of September 30, 2016 and December 31, 2015:

	September 30, 2016		December 31, 2015
Rent payable	$	-	$	52
Uncertain tax positions		3,556		3,425
DOJ settlement (indemnified by RedPath)		1,000		2,500
Other		59		201
	$	4,615	$	6,178